Zobrazeno 1 - 10
of 95
pro vyhledávání: '"Yung Hung Luo"'
Autor:
Jin-Yuan Shih, Yung-Hung Luo, Gee-Chen Chang, John Wen-Cheng Chang, Chin-Chou Wang, Tsung-Ying Yang, Wei-Tse Fang, Wen-Yi Shau
Publikováno v:
Journal of the Formosan Medical Association, Vol 123, Iss 8, Pp 875-881 (2024)
Background: Lorlatinib is a brain-penetrant, third-generation anaplastic lymphoma kinase (ALK) inhibitor indicated for ALK-positive metastatic non-small cell lung cancer (NSCLC). In a global phase II study, patients who experience disease progression
Externí odkaz:
https://doaj.org/article/a761d4469e6046f0991578a068010259
Autor:
Anita S La'ah, Ping‐Hsing Tsai, Aliaksandr A. Yarmishyn, Lo‐Jei Ching, Chih‐Ying Chen, Yueh Chien, Jerry Chieh‐Yu Chen, Ming‐Long Tsai, Yi‐Chen Chen, Chun Ma, Po‐Kuei Hsu, Yung‐Hung Luo, Yuh‐Min Chen, Guang‐Yuh Chiou, Kai‐Hsi Lu, Wen‐Chang Lin, Yu‐Ting Chou, Mong‐Lien Wang, Shih‐Hwa Chiou
Publikováno v:
Advanced Science, Vol 11, Iss 38, Pp n/a-n/a (2024)
Abstract NK2 Homeobox 1 (NKX2‐1) is a well‐characterized pathological marker that delineates lung adenocarcinoma (LUAD) progression. The advancement of LUAD is influenced by the immune tumor microenvironment through paracrine signaling. However,
Externí odkaz:
https://doaj.org/article/3d23080e0cf742cf9d8128334fa2c505
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Background: Programmed cell death protein 1 ligand 1 (PD-L1) expression alone may not be the optimal predictor of immunotherapy (IO) efficacy in advanced non-small cell lung cancer (NSCLC). Evaluation of circulating immune signatures using mass cytom
Externí odkaz:
https://doaj.org/article/8791fb4a97c24b9189c6b513f7aceb20
Autor:
Bin-Chi Liao, Nai-Jung Chiang, Gee-Chen Chang, Wu-Chou Su, Yung-Hung Luo, Inn-Wen Chong, Tsung-Ying Yang, Chun-Liang Lai, Te-Chun Hsia, Ching-Liang Ho, Kang-Yun Lee, Chin-Fu Hsiao, Fan-Chen Ku, Wei-Tse Fang, James Chih-Hsin Yang
Publikováno v:
JCO Global Oncology, Iss 10 (2024)
PURPOSETissue-based next-generation sequencing (NGS) analysis is highly recommended for patients with advanced/metastatic non–small cell lung cancer (NSCLC). We investigated a specific patient population with NSCLC that required tissue-based NGS an
Externí odkaz:
https://doaj.org/article/e503bb76a5e74e31a0d489729debaa21
Autor:
Yuan‐Hung Wu, Heng‐sheng Chao, Chi‐Lu Chiang, Yung‐Hung Luo, Chao‐Hua Chiu, Sang‐Hue Yen, Chun‐Yu Liu, Jeng‐Fong Chiou, Thierry Burnouf, Yin‐Ju Chen, Peng‐Yuan Wang, Tsu‐Yi Chao, Shih‐Ming Hsu, Long‐Sheng Lu
Publikováno v:
Thoracic Cancer, Vol 14, Iss 25, Pp 2591-2600 (2023)
Abstract Background Systemic therapy is the primary treatment for advanced thymic malignancies. However, there is an urgent need to improve clinical outcome. Personalized treatment based on predictive biomarkers is a potential approach to address thi
Externí odkaz:
https://doaj.org/article/5371253bf06e44099b9f64200c02042b
Autor:
Chi‐Lu Chiang, Hsiang‐Ling Ho, Yi‐Chen Yeh, Cheng‐Chia Lee, Hsu‐Ching Huang, Chia‐I Shen, Yung‐Hung Luo, Yuh‐Min Chen, Chao‐Hua Chiu, Teh‐Ying Chou
Publikováno v:
Thoracic Cancer, Vol 14, Iss 14, Pp 1251-1259 (2023)
Abstract Background Cell‐free tumor DNA (ctDNA) obtained through liquid biopsy is useful for the molecular analysis of advanced non‐small‐cell lung cancer (NSCLC). Few studies have directly compared analysis platforms in terms of their diagnost
Externí odkaz:
https://doaj.org/article/35276478879c45219cbe12a325323d47
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundPulmonary infections are a crucial health concern for patients with advanced non–small-cell lung cancer (NSCLC). Whether the clinical outcome of pulmonary infection is influenced by immunotherapy(IO) remains unclear. By evaluating immune
Externí odkaz:
https://doaj.org/article/e47016c1e7a845a4945899bdc26960c0
Autor:
Qi Zhao, Jianfeng Li, Xuejun Li, Jian-Guo Zhou, Benjamin Frey, Hu Ma, Haitao Wang, Peng Luo, Markus Hecht, Udo Gaipl, Shixiang Wang, Yi Xiong, Yihao Zhang, Minjun Chen, Yung-Hung Luo
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 1 (2024)
Background Immunotherapies targeting immune checkpoints have gained increasing attention in cancer treatment, emphasizing the need for predictive biomarkers. Circular RNAs (circRNAs) have emerged as critical regulators of tumor immunity, particularly
Externí odkaz:
https://doaj.org/article/c918fd42f1644b83b574fa49efdc8fdc
Autor:
Yuan‐Hung Wu, Yu‐Mei Kang, Yu‐Wen Hu, Keng‐Li Lan, Sang‐Hue Yen, Tzu‐Yu Lai, Tien‐Li Lan, Yuh‐Min Chen, Chao‐Hua Chiu, Yung‐Hung Luo, Heng‐sheng Chao, Chi‐Lu Chiang, Tsu‐Hui Shiao, Chao‐Neng Yang, Wen‐Hu Hsu, Yu‐Chung Wu, Han‐Shui Hsu, Jung‐Jyh Hung, Chien‐Sheng Huang, Po‐Kuei Hsu, Yi‐Wei Chen
Publikováno v:
Thoracic Cancer, Vol 14, Iss 7, Pp 654-661 (2023)
Abstract Background Stereotactic ablative radiotherapy (SABR) is now the standard of care for patients with inoperable early‐stage lung cancer. Many of these patients are elderly. EGFR (epidermal growth factor receptor) mutation is also common in t
Externí odkaz:
https://doaj.org/article/5b089288371243c5a3bbf99975a9d3fc
Autor:
Chia-I Shen, Chi-Lu Chiang, Tsu-Hui Shiao, Yung-Hung Luo, Heng-Sheng Chao, Hsu-Ching Huang, Chao-Hua Chiu
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-7 (2022)
Abstract Detection of driver gene mutations is important in advanced NSCLC. The cobas EGFR mutation test is a mutant allele-specific real-time PCR assay with limitation owing to its primer design. Next-generation sequencing-based assay has a higher m
Externí odkaz:
https://doaj.org/article/39e8260d6c884d1ba0f6a3c5291782a3